Jatenzo Cost in Pennsylvania 2026: Cash Price, Insurance, Medicaid, and Savings

What Is the Cash Price of Jatenzo in Pennsylvania in 2026?

The retail cash price for Jatenzo in Pennsylvania sits around $900 per month in 2026, matching the manufacturer list price set by Tolmar Pharmaceuticals. Without insurance or a savings program, most Pennsylvania pharmacies, including major chains such as CVS, Rite Aid, and Giant Pharmacy, dispense Jatenzo at or close to that list price. No meaningful generic competition exists yet, because the FDA granted Jatenzo exclusivity protections after its approval in March 2019.

Why Jatenzo Is Priced at $900

Oral testosterone delivery is pharmacologically complex. Testosterone itself is destroyed in first-pass hepatic metabolism when taken by mouth, which is why earlier oral testosterone products failed or carried liver toxicity signals. Jatenzo uses a lipophilic undecanoate ester that is absorbed through intestinal lymphatics, bypassing first-pass metabolism. The key phase 3 trial by Swerdloff et al. (J Clin Endocrinol Metab, 2020; N=166) confirmed that 87% of men with hypogonadism reached average total testosterone concentrations in the normal range (300 to 1,000 ng/dL) during the 12-week maintenance period. That clinical differentiation, combined with patent protection, supports premium pricing.

Price Comparison With Other TRT Options in Pennsylvania

Jatenzo's $900 monthly cash price is substantially higher than generic testosterone cypionate injections, which run roughly $30 to $80 per month at Pennsylvania pharmacies, or testosterone gels such as AndroGel 1.62%, which list near $500 per month but also carry lower-cost generics. Pennsylvania residents paying cash should request a GoodRx or RxSaver coupon at checkout, which may reduce the Jatenzo price modestly, though discounts on branded specialty drugs tend to be smaller than on generics. The FDA's drug pricing transparency resources provide background on how list prices relate to actual pharmacy acquisition costs.

Does Pennsylvania Medicaid Cover Jatenzo?

Pennsylvania Medicaid (Medical Assistance) covers Jatenzo for male hypogonadism, subject to prior authorization. The Pennsylvania Department of Human Services administers pharmacy benefits through managed care organizations (MCOs) such as Highmark Wholecare, UPMC for You, and Geisinger Health Plan. Each MCO applies its own prior authorization criteria, but the clinical standard across plans generally requires documented low serum testosterone (typically below 300 ng/dL on two morning fasting measurements) and symptoms consistent with hypogonadism.

How to Get Prior Authorization Through PA Medicaid

Your prescribing provider submits a prior authorization request to your MCO's pharmacy benefit manager. Supporting documentation usually includes two testosterone lab values, a clinical note documenting symptoms, and confirmation that the diagnosis is primary or secondary hypogonadism rather than age-related decline alone. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism defines diagnostic thresholds that Pennsylvania MCOs often reference directly in their coverage criteria.

What Happens if PA Medicaid Denies the Claim

If your MCO issues a denial, Pennsylvania law provides a right to appeal. Your provider can submit a peer-to-peer review request, typically within 14 days of the denial. A pharmacist or physician at the MCO reviews the case. If that fails, a formal external grievance is available under 42 CFR Part 438, which governs Medicaid managed care appeals nationwide. Documenting failed trials of lower-cost testosterone formulations (injectable testosterone cypionate, for example) strengthens the appeal because formulary step therapy is a common denial reason.

Which Commercial Insurance Plans Cover Jatenzo in Pennsylvania?

Major commercial insurers in Pennsylvania, including Highmark, Independence Blue Cross, UPMC Health Plan, and Aetna, list Jatenzo on specialty or non-preferred branded tiers. Coverage exists on most plans, but prior authorization is nearly universal. Step therapy requirements are common: many Pennsylvania plans require documented failure or intolerance of at least one injectable testosterone product before approving Jatenzo.

Tier Placement and Out-of-Pocket Cost Estimates

On a typical Pennsylvania commercial plan in 2026, Jatenzo lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 copays range from roughly $60 to $150 per 30-day supply after the deductible. Tier 4 copays can reach $200 to $400 per fill. Patients with high-deductible health plans (HDHPs) may pay the full negotiated rate, often $600 to $800 per month, until the deductible is met. The American Urological Association's 2022 hypogonadism guideline notes that cost and administration route are legitimate clinical factors when choosing among testosterone formulations.

Prior Authorization Requirements in Pennsylvania

Prior authorization documentation for commercial plans typically mirrors Medicaid requirements: low testosterone on two separate morning draws, documented symptoms, and a signed statement that the prescriber has considered or tried other formulations. Pennsylvania's Act 146 of 2022 limits step therapy to evidence-based protocols and requires insurers to respond to step-therapy exemption requests within 72 hours for urgent cases and 30 days for standard requests, per Pennsylvania Insurance Department guidance.

How Does the Tolmar Savings Card Work in Pennsylvania?

Tolmar Pharmaceuticals offers a co-pay savings card for Jatenzo that can reduce eligible commercially insured patients' out-of-pocket cost to $0 per month, subject to a monthly maximum benefit and annual cap. Pennsylvania residents who have commercial insurance and a valid Jatenzo prescription can enroll at the Tolmar patient savings portal. The card is processed at the pharmacy like a secondary insurance card.

Eligibility Rules for the Tolmar Card

The savings card explicitly excludes patients whose prescriptions are covered by a federal or state government program. This means Pennsylvania Medicaid recipients, Medicare Part D enrollees, and patients covered by CHIP do not qualify. Using a manufacturer co-pay card while also billing a federal program is prohibited under federal anti-kickback statutes, per CMS guidance. Patients who are commercially insured but also have Medicare as a secondary payer should confirm eligibility with Tolmar's patient support line before enrolling.

How Much Does the Card Actually Save?

For a patient whose insurer has processed Jatenzo on Tier 3 with a $120 copay, the savings card covers that $120, bringing the monthly cost to $0. For a patient on Tier 4 with a $350 copay, the card covers up to the card's stated maximum (the specific cap is updated annually by Tolmar, so confirm the current limit when enrolling). The FDA's patient assistance program resources provide general context on how manufacturer assistance programs interact with pharmacy benefit managers.

Is Compounded Oral Testosterone Undecanoate Legal in Pennsylvania?

Yes. In Pennsylvania, licensed 503A compounding pharmacies may compound oral testosterone undecanoate for individual patients who have a valid prescription from a licensed prescriber. The drug is not on the FDA's list of drugs withdrawn from the market for safety reasons, and it is not a commercially available active pharmaceutical ingredient (API) that is off-limits to compounders. The 503A pathway requires a patient-specific prescription, meaning bulk compounding for office dispensing is not permitted.

503A vs. 503B in Pennsylvania

503A pharmacies serve individual patients based on specific prescriptions. 503B outsourcing facilities produce larger batches for healthcare facilities without patient-specific prescriptions. Both types operate in Pennsylvania. The FDA's compounding regulations under 21 U.S.C. 503A permit compounding when the drug is not essentially a copy of a commercially available product. Because compounded testosterone undecanoate differs in formulation from the commercial Jatenzo capsule (different excipients, potentially different dose strengths), most 503A pharmacies argue it is not a copy. Prescribers and patients should confirm this interpretation with the specific pharmacy.

Cost of Compounded Oral Testosterone Undecanoate in Pennsylvania

This is where cost-sensitive Pennsylvania patients may find the most significant difference. Compounded oral testosterone undecanoate from a licensed Pennsylvania 503A pharmacy may cost as little as $0 to $100 per month depending on dose, quantity, and pharmacy pricing, compared with Jatenzo's $900 list price. The tradeoff is that compounded products have not undergone the FDA's premarket review for efficacy and consistency. The Swerdloff et al. Trial demonstrating Jatenzo's pharmacokinetic reliability applies to the commercial formulation specifically, not to compounded versions. Patients choosing the compounded route should use a pharmacy registered with the Pennsylvania State Board of Pharmacy and request a certificate of analysis for each batch.

The HealthRX clinical team uses the following decision framework when Pennsylvania patients ask about Jatenzo versus compounded oral testosterone undecanoate. Patients with active commercial insurance and Tolmar savings card eligibility generally pay $0 per month for Jatenzo and face no meaningful reason to pursue compounded alternatives. Patients on Pennsylvania Medicaid with prior authorization approval also access Jatenzo at low or no cost. Cash-paying patients without insurance are the group for whom compounded oral testosterone undecanoate offers the clearest cost advantage, provided they use a licensed 503A pharmacy and understand the difference in regulatory oversight.

Can Pennsylvania Patients Get Jatenzo via Telehealth?

Yes. Pennsylvania permits telehealth prescribing of controlled substances, including Schedule III testosterone products, under regulations aligned with the DEA's temporary telemedicine flexibilities. As of 2025, the DEA has extended telemedicine prescribing of controlled substances through its special registration framework. Pennsylvania-licensed telehealth providers may prescribe Jatenzo after conducting a synchronous audio-video visit that includes review of recent testosterone lab results. The DEA telemedicine rules do not require an in-person visit before issuing an initial controlled substance prescription when the prescriber complies with state and federal telemedicine standards.

What a Telehealth TRT Visit in Pennsylvania Requires

A typical telehealth Jatenzo visit in Pennsylvania includes a review of two morning fasting testosterone levels drawn at a local lab (LabCorp and Quest both operate throughout Pennsylvania), a symptom assessment using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire, a blood pressure check (Jatenzo carries an FDA warning for increases in blood pressure, and the prescribing label recommends monitoring before and during therapy), and a review of cardiovascular risk factors. The Endocrine Society guideline recommends against initiating testosterone therapy in men with recent myocardial infarction, stroke, or untreated severe sleep apnea.

Telehealth Platforms Operating in Pennsylvania

Several national telehealth platforms prescribe Jatenzo to Pennsylvania residents, including HealthRX. After the initial video consultation and lab review, prescriptions are transmitted electronically to a Pennsylvania pharmacy of the patient's choice or, where applicable, to a 503A compounding pharmacy. Follow-up visits are typically scheduled at 3 months to assess symptom response, repeat testosterone levels, hematocrit, and PSA per the Endocrine Society monitoring recommendations.

What Are the Clinical Basics of Jatenzo That Affect Cost Decisions?

Understanding the drug's pharmacology helps explain why some insurers require step therapy before approving it. Jatenzo is the first FDA-approved oral testosterone replacement approved in the United States since methyltestosterone, which was discontinued due to hepatotoxicity. Jatenzo avoids hepatotoxicity because lymphatic absorption bypasses the liver on the first pass.

Dosing and Administration

The starting dose is 237 mg twice daily with food. After 4 weeks, the prescriber adjusts based on a serum testosterone drawn 6 hours after the morning dose (the mid-dose Cmax check the FDA approved for titration). The dose may be increased to 316 mg twice daily or reduced to 158 mg twice daily. The FDA prescribing label specifies that Jatenzo must be taken with food because fat in the meal drives lymphatic absorption. A missed dose taken without food may produce subtherapeutic levels.

Key Safety Signals That Influence Insurer Criteria

The FDA added a boxed warning for blood pressure increases. In the Swerdloff et al. Trial, 21% of participants required initiation or dose escalation of antihypertensive medications during the study. Mean systolic blood pressure increased by approximately 3.5 mmHg from baseline. Pennsylvania insurers sometimes cite this cardiovascular signal as a reason to require documented failure of lower-risk formulations first. The American Heart Association's hypertension guidelines classify a 3 to 5 mmHg systolic increase as clinically meaningful in patients already at elevated cardiovascular risk, which is why blood pressure screening before starting Jatenzo is essential.

Hematocrit and PSA Monitoring Costs in Pennsylvania

Ongoing testosterone monitoring adds to the total cost of therapy. A comprehensive metabolic panel, testosterone level, hematocrit, and PSA test panel at a Pennsylvania LabCorp or Quest location costs roughly $100 to $300 without insurance, or may be covered at no additional cost under preventive benefit provisions depending on plan design. The Endocrine Society guideline recommends checking hematocrit at 3 and 6 months and then annually, and PSA at 3 to 6 months and then per age-appropriate screening recommendations.

Cheapest Ways to Get Jatenzo (or Its Equivalent) in Pennsylvania

Option 1: Tolmar Savings Card Plus Commercial Insurance

For commercially insured Pennsylvania patients, enrolling in the Tolmar co-pay savings card and submitting a prior authorization request through their insurer is the lowest-cost path to the FDA-approved product. Monthly out-of-pocket cost may reach $0. The FDA's guidance on patient assistance programs offers general background on how these programs function within the broader drug pricing system.

Option 2: Pennsylvania Medicaid With Prior Authorization

Medicaid-enrolled Pennsylvania residents who meet prior authorization criteria pay $0 to $3 per prescription per Pennsylvania's co-pay schedule for preferred drugs. This path requires provider documentation of low testosterone and symptoms, but it represents the most affordable access to brand-name Jatenzo for low-income patients.

Option 3: Compounded Oral Testosterone Undecanoate via 503A Pharmacy

Cash-paying patients without insurance, or those whose insurance denies coverage after exhausting appeals, may access compounded oral testosterone undecanoate from a licensed Pennsylvania 503A pharmacy for $0 to $100 per month. The prescriber writes a patient-specific prescription specifying the dose (commonly 200 to 400 mg twice daily, though dosing is individualized), the formulation (oil-filled capsule), and the quantity. The FDA's 503A compounding framework governs quality standards for these preparations. Patients should confirm that their chosen pharmacy holds an active Pennsylvania State Board of Pharmacy license and compounding accreditation from PCAB (Pharmacy Compounding Accreditation Board).

Option 4: GoodRx and Other Discount Programs

GoodRx and RxSaver list Jatenzo coupons that may trim $50 to $150 off the retail cash price at participating Pennsylvania pharmacies. These programs are most useful for patients who cannot use the Tolmar savings card (for example, those whose insurance cannot process the card at their pharmacy) or who are in a HDHP deductible phase. These coupons cannot be combined with insurance billing; they function as cash-pay alternatives.